- Cantourage and Cannim deepen their partnership and expand treatment options for patients in Germany from today, with the highly potent sativa-dominant strain “Wild Thailand”
- HummingBud is the second Jamaican medicinal cannabis flower product after Lumir to be available in German pharmacies thanks to Cantourage
- The product is characterised by sustainable cultivation and gentle production, without the use of irradiation.
With Hummingbud, Cantourage and Cannim are bringing a further medicinal cannabis flower from Jamaica to German dispensaries. The sativa-dominant strain “Wild Thailand” is available to patients in Germany as of today. After Lumir, HummingBud is the second Jamaican cannabis flower available in Germany from Cannim. The plant is grown on the high plains of Jamaica and thus under optimal climate conditions.
The further processing and production of the pharmaceutical drug is handled by Cantourage in Germany. This uses a particularly gentle process for microbial reduction, without irradiation. This allows Cantourage to significantly reduce the microbial load as needed while maintaining the unique natural terpene profile of the flowers. Compared to non-irradiated products, this ensures consistent quality and continuous supply of Cantourage products to patients. Details can be found by healthcare professionals on the Cantourage website (www.cantourage.com).
Philip Schetter, CEO of Cantourage, comments: “Following the launch of Lumir, the first Jamaican medical cannabis in Germany, we are delighted to be able to expand our product range today. With HummingBud, we have now brought the second Jamaican medical cannabis product to German pharmacies, significantly expanding treatment options for patients. We expect that this second product from Jamaica will also be in high demand from doctors, pharmacists and patients.”
Dr. Sven Sauer, Managing Director of Cannim says: “With HummingBud we are bringing another of our products from the Jamaican highlands to German pharmacies. The climate conditions in Jamaica allow for a sustainable and, above all, natural cultivation of the Wild Thailand cultivar HummingBud. In addition to the high product quality, this is a further aspect that is highly appreciated by pharmacies and especially patients.”
HummingBud can be ordered now directly from Cantourage under PZN 17491410.
Cantourage is a leading European medical cannabis company. The Berlin-based company was founded in 2019 by industry pioneers Dr. Florian Holzapfel, Norman Ruchholtz and Patrick Hoffman. Cantourage enables producers from across the world to bring their product into the growing and profitable European market more quickly and cheaply, while guaranteeing and further developing highest European quality standards. It offers products in all relevant market segments: dried flowers, extracts and Dronabinol.
Established in 2017, Cannim was founded on the vision of moving cannabis from the darkness into the light and helping bring the benefits of medicinal cannabis to the world. Since that time, Cannim has invested in farms, GMP production facilities and initiating research in Jamaica and Australia utilizing expertise for these activities from Israel, Jamaica, the USA, UK and Australia. It operates with an international network of EU GMP (Good Manufacturing Practice) manufacturers and channels to market. Cannim’s circular integrated business is built on three key pillars of Safety, Science Scale © and is focused on delivering premium quality products, consistently and reliably to patients globally. This long-term vision is integral to Cannim’s approach to improving its consumers’ health and wellness, delivering ‘Better Balanced Bodies’ and establishing world-leading medicinal and wellness cannabis brands.